Z Culig

Summary

Affiliation: University of Innsbruck
Country: Austria

Publications

  1. ncbi Molecular biology of the androgen receptor: from molecular understanding to the clinic
    I E Eder
    Department of Urology, University of Innsbruck, Austria
    Eur Urol 40:241-51. 2001
  2. ncbi Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway
    Hannes Neuwirt
    Division of General Internal Medicine, Department of Internal Medicine, Innsbruck Medical University, A 6020 Innsbruck, Austria
    Int J Oncol 29:503-12. 2006
  3. ncbi p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6
    Jose D Debes
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 65:5965-73. 2005
  4. ncbi The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer
    Barbara Comuzzi
    Department of Urology, Innsbruck Medical University, A 6020 Innsbruck, Austria
    J Pathol 204:159-66. 2004
  5. ncbi Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells
    Karina Pfeil
    Department of Urology, University of Innsbruck, Austria
    Prostate 58:259-68. 2004
  6. ncbi Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth
    Zoran Culig
    Department of Urology, University of Innsbruck, A 6020 Innsbruck, Austria
    Mol Cell Endocrinol 197:231-8. 2002
  7. ncbi Androgen receptors in prostate cancer
    Z Culig
    Department of Urology, University of Innsbruck, Anichstrasse 35, A 6020 Innsbruck, Austria
    Endocr Relat Cancer 9:155-70. 2002
  8. ncbi Expression and function of androgen receptor coactivators in prostate cancer
    Zoran Culig
    Department of Urology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Steroid Biochem Mol Biol 92:265-71. 2004
  9. ncbi Androgen axis in prostate cancer
    Zoran Culig
    Department of Urology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Cell Biochem 99:373-81. 2006
  10. ncbi Androgen receptors in prostate cancer
    Zoran Culig
    Department of Urology, University of Innsbruck, Austria
    J Urol 170:1363-9. 2003

Collaborators

Detail Information

Publications59

  1. ncbi Molecular biology of the androgen receptor: from molecular understanding to the clinic
    I E Eder
    Department of Urology, University of Innsbruck, Austria
    Eur Urol 40:241-51. 2001
    ..This review will summarize the most important findings about the AR and the androgen signaling pathway to improve the understanding of prostate diseases and novel treatment strategies that may be useful in the clinic...
  2. ncbi Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway
    Hannes Neuwirt
    Division of General Internal Medicine, Department of Internal Medicine, Innsbruck Medical University, A 6020 Innsbruck, Austria
    Int J Oncol 29:503-12. 2006
    ..We therefore recommend further investigation of the anticancer activity of this biocidal oliguanidine...
  3. ncbi p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6
    Jose D Debes
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 65:5965-73. 2005
    ....
  4. ncbi The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer
    Barbara Comuzzi
    Department of Urology, Innsbruck Medical University, A 6020 Innsbruck, Austria
    J Pathol 204:159-66. 2004
    ..CBP protein was detected in all 26 specimens by immunohistochemistry. The results suggest that up-regulation of CBP during androgen ablation may be relevant to the failure of endocrine therapy in patients with prostate carcinoma...
  5. ncbi Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells
    Karina Pfeil
    Department of Urology, University of Innsbruck, Austria
    Prostate 58:259-68. 2004
    ..Using cell culture models representing different tumor stages, we explored the effect of inhibition of this survival pathway on the induction of apoptosis...
  6. ncbi Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth
    Zoran Culig
    Department of Urology, University of Innsbruck, A 6020 Innsbruck, Austria
    Mol Cell Endocrinol 197:231-8. 2002
    ..In contrast, IL-6 mRNA and protein expression were detectable in high passages of LNCaP-IL-6+ cells. Thus changes in signal transduction occur in prostate cancer cells after prolonged IL-6 treatment..
  7. ncbi Androgen receptors in prostate cancer
    Z Culig
    Department of Urology, University of Innsbruck, Anichstrasse 35, A 6020 Innsbruck, Austria
    Endocr Relat Cancer 9:155-70. 2002
    ..New experimental therapies for prostate cancer are aimed to down-regulate AR expression and to overcome difficulties which occur because of the acquisition of agonistic properties of commonly used antiandrogens...
  8. ncbi Expression and function of androgen receptor coactivators in prostate cancer
    Zoran Culig
    Department of Urology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Steroid Biochem Mol Biol 92:265-71. 2004
    ..In summary, several abnormalities in AR coactivator expression and function are associated with prostate cancer progression...
  9. ncbi Androgen axis in prostate cancer
    Zoran Culig
    Department of Urology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Cell Biochem 99:373-81. 2006
    ..There is experimental evidence showing that prostate tumor growth in vitro and in vivo is inhibited following administration of chemopreventive drugs or antisense oligonucleotides that downregulate AR mRNA and protein expression...
  10. ncbi Androgen receptors in prostate cancer
    Zoran Culig
    Department of Urology, University of Innsbruck, Austria
    J Urol 170:1363-9. 2003
    ..For a better understanding of prostate carcinoma events it is necessary to present findings on the regulation of AR target genes, AR interaction with associated proteins, ligand independent activation and point mutations...
  11. ncbi Role of the androgen receptor axis in prostate cancer
    Zoran Culig
    Department of Urology, University of Innsbruck, Innsbruck, Austria
    Urology 62:21-6. 2003
    ..It is hoped that continuing research on AR expression and function in prostate cancer will pave the way for new therapeutic strategies...
  12. ncbi Interleukin-6 regulation of prostate cancer cell growth
    Zoran Culig
    Department of Urology, Innsbruck Medical University, Innsbruck, Austria
    J Cell Biochem 95:497-505. 2005
    ..Anti-IL-6 antibodies showed an inhibitory effect on the PC-3 xenograft. However, the development of this therapy in prostate cancer is in early stages...
  13. ncbi Antiandrogens in prostate cancer endocrine therapy
    Z Culig
    Department of Urology, University of Innsbruck, Austria
    Curr Cancer Drug Targets 4:455-61. 2004
    ..There are indications that expression of some of these proteins is altered in prostate cancer, a fact which might be important for improvement of endocrine therapy...
  14. ncbi Androgen receptor cross-talk with cell signalling pathways
    Zoran Culig
    Department of Urology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Growth Factors 22:179-84. 2004
    ..Studies on AR co-activators implicated in ligand-independent activation may further improve understanding of cross-talk between signalling pathways...
  15. ncbi Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
    Z Culig
    Department of Urology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Endocr Relat Cancer 12:229-44. 2005
    ..Similarly, activation of the AR by phosphorylated protein kinase B, Akt, has also been reported in prostate cancer. Activation of the Akt pathway contributes to increased survival of prostate tumour cells...
  16. ncbi Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy
    Z Culig
    Department of Urology, University of Innsbruck, Innsbruck, Austria
    Am J Pharmacogenomics 1:241-9. 2001
    ..Novel experimental therapies that down-regulate AR expression have been developed; they include the application of ribozymes and antisense oligonucleotides...
  17. ncbi Expression and function of androgen receptor in carcinoma of the prostate
    Z Culig
    Department of Urology, University of Innsbruck, A 6020 Innsbruck, Austria
    Microsc Res Tech 51:447-55. 2000
    ..This study also contains a chapter on androgen receptor-associated proteins, coactivators, and coreppressors and their possible role in pathological situations...
  18. pmc Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system
    Z Culig
    Department of Urology, University of Innsbruck, Austria
    Br J Cancer 81:242-51. 1999
    ..These findings may have repercussions on the natural course of prostate cancer with androgen deprivation and on strategies of therapeutic intervention...
  19. ncbi Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype
    A Hobisch
    Department of Urology, University of Innsbruck, Innsbruck A-6020, Austria
    Clin Cancer Res 7:2941-8. 2001
    ..CONCLUSIONS: Long-term treatment of LNCaP human prostate cancer cells with IL-6 leads to abolishment of inhibitory growth response. In contrast to control cells, the LNCaP-IL-6+ subline expresses IL-6 mRNA and protein...
  20. ncbi Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model
    A Hobisch
    Department of Urology, University of Innsbruck, Austria
    Urol Int 65:73-9. 2000
    ..The present study provides new information that is useful for a better understanding of therapy-refractory prostate cancer. It is also important for the development of new therapy strategies for advanced carcinoma of the prostate...
  21. pmc Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells
    Z Culig
    Department of Urology, University of Innsbruck, Austria
    Br J Cancer 78:1004-11. 1998
    ..Our findings reveal that monocyte-derived IL-1beta inhibits the proliferation of androgen-responsive prostate tumour cells and reduces AR and PSA levels...
  22. ncbi Mechanism of androgen receptor activation and possible implications for chemoprevention trials
    H Klocker
    Department of Urology, University of Innsbruck, Austria
    Eur Urol 35:413-9. 1999
    ..It is not yet clear if similar changes also occur in normal or premalignant prostate epithelial cells and are thus relevant for prevention trials which interfere with androgen hormone signaling...
  23. pmc Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells
    M V Cronauer
    Department of Urology, University of Innsbruck, Austria
    Br J Cancer 82:39-45. 2000
    ..In summary, these studies show that bFGF is a potent negative regulator of AR protein expression in the human prostate cancer cell line LNCaP...
  24. ncbi The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1
    I T Cavarretta
    Department of Urology, Innsbruck Medical University, Innsbruck, Austria
    Oncogene 26:2822-32. 2007
    ..Our data support the concept of anti-IL-6 targeted therapy in therapy-resistant prostate cancer...
  25. ncbi Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone
    Z Culig
    Department of Urology, University of Innsbruck, Austria
    Mol Endocrinol 7:1541-50. 1993
    ..This pattern of ligand-dependent trans-activation may have significance in the process controlling the progression of prostatic carcinoma...
  26. ncbi An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6
    Hannes Steiner
    Department of Urology, University of Innsbruck, Anichstrasse 35, A 6020 Innsbruck, Austria
    Eur J Cancer 40:1066-72. 2004
    ..Because of the upregulation of IL-6 in patients with prostate cancer, these findings might be clinically relevant...
  27. ncbi Androgen receptor point mutations as the underlying molecular defect in 2 patients with androgen insensitivity syndrome
    C Radmayr
    Department of Urology, University of Innsbruck, Austria
    J Urol 158:1553-6. 1997
    ..The functional properties of these mutant receptors regarding hormone binding and transactivation were characterized in 2 patients and offered a possible treatment modality for a male pseudohermaphroditism newborn...
  28. ncbi [Clinical consequences of androgen receptor malfunction]
    H Klocker
    Universitäitsklinik für Urologie, Medizinische Universitat Innsbruck, Anichstrasse 35, A 6020 Innsbruck, Austria
    Verh Dtsch Ges Pathol 88:122-9. 2004
    ..Androgen ablation therapy puts prostate tumor cells under selection pressure that finally results in development of a hyperreactive androgen receptor that is activated under the conditions of therapy...
  29. doi Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor
    Kamilla Malinowska
    Department of Urology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Endocr Relat Cancer 16:155-69. 2009
    ..Taken together, data in the present study demonstrate that IL-6 may cause growth of androgen receptor-positive tumours in vitro and in vivo through activation of the androgen receptor...
  30. pmc The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function
    Barbara Comuzzi
    Department of Urology, University of Innsbruck, Innsbruck, Austria
    Am J Pathol 162:233-41. 2003
    ....
  31. ncbi Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells
    Sonia Godoy-Tundidor
    Department of Urology, University of Innsbruck, A 6020 Innsbruck, Austria
    Clin Cancer Res 8:2356-61. 2002
    ....
  32. doi Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma
    Ilaria Teresa Cavarretta
    Department of Urology, Innsbruck Medical University, Anichstrasse, Innsbruck, Austria
    Adv Exp Med Biol 617:547-55. 2008
    ..CNTO 328, in our experimental conditions, is able to render LNCaP-IL-6+ cells more sensitive to apoptosis. These data support the concept of anti-IL-6 therapy in human PC...
  33. ncbi The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide
    Alfred Hobisch
    Department of Urology, General Hospital Feldkirch, Feldkirch, Austria
    Prostate 66:413-20. 2006
    ..However, little attention has been paid to the androgen receptor-signaling pathway in the development of therapy resistance in patients who receive chronic treatment with a non-steroidal anti-androgen...
  34. doi Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer
    Kamilla Malinowska
    Department of Urology and Biocenter, Innsbruck Medical University, Innsbruck, Austria
    Prostate 69:1109-18. 2009
    ..Androgen receptor (AR) signaling is implicated in prostate cancer progression. Therefore, identification of AR downstream genes is potentially important for selection of novel markers and therapy targets in prostate cancer...
  35. pmc Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases
    Hannes Neuwirt
    Department of Urology, Biocenter, Innsbruck Medical University, Innsbruck, Austria
    Am J Pathol 174:1921-30. 2009
    ..In summary, we show that SOCS-1 is expressed in prostate cancer both in vitro and in vivo and acts as a negative growth regulator...
  36. ncbi Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression
    Alfred Hobisch
    Department of Urology, University of Innsbruck, Innsbruck, Austria
    Prostate 59:401-8. 2004
    ..Regulation of growth and survival of prostate cancer cells during intermittent androgen withdrawal has not been studied in appropriate models yet...
  37. ncbi Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase
    Sonia Godoy-Tundidor
    Department of Urology, Innsbruck Medical University, Innsbruck, Austria
    Prostate 64:209-16. 2005
    ..In order to understand better the mechanisms controlling proliferation and intracellular signaling by these cytokines in advanced prostate carcinoma, we performed studies in 22Rv1 cells derived from the relapsed xenograft CWR22R...
  38. pmc Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway
    Hannes Steiner
    Departments of Urology, Pathology, and Medical Chemistry and Biochemistry, University of Innsbruck, Innsbruck, Austria
    Am J Pathol 162:655-63. 2003
    ..These findings could be relevant to understand the role of IL-6 in prostate cancer progression...
  39. ncbi Studies on androgen receptor mutations and amplification in human prostate cancer
    Zoran Culig
    Department of Urology, University of Innsbruck, Innsbruck, Austria
    Methods Mol Med 81:267-75. 2003
  40. doi SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling
    Martin Puhr
    Department of Urology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Endocr Relat Cancer 17:525-38. 2010
    ..On the basis of the present results, we propose that SOCS-3 is a novel modulator of FGF-2-regulated cellular events in prostate cancer...
  41. pmc Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells
    Frédéric R Santer
    Department of Urology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Endocr Relat Cancer 17:241-53. 2010
    ..Collectively, these data suggest that selective targeting of IL-6TS might allow to refine the currently available experimental anti-IL-6 therapies against PC...
  42. doi Oligomeric proanthocyanidin complexes (OPC) exert anti-proliferative and pro-apoptotic effects on prostate cancer cells
    Hannes Neuwirt
    Department of Urology, Innsbruck Medical University, Innsbruck, Austria
    Prostate 68:1647-54. 2008
    ..Since a role for OPC in cancer prevention was postulated, we asked whether they have an effect on prostate cancer cells...
  43. ncbi Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide
    Michael Mitterberger
    Department of Urology, Innsbruck Medical University, Innsbruck, Austria
    Prostate 67:1194-201. 2007
    ..In the present study, we have asked whether changes in response to the tumor-selective apoptosis inducer TNF-related apoptosis-inducing ligand (TRAIL) occur in LNCaP-Bic cells...
  44. ncbi Effects of sorafenib on proliferation of hormone-sensitive and hormone-insensitive prostate cancer cells
    Z Culig
    Medical University Innsbruck, Innsbruck, Austria General Hospital Feldkirch, Feldkirch, Austria
    J Clin Oncol 27:e16092. 2009
    ..The mechanisms of its action in advanced prostate tumors are not investigated so far. The aim of the present study was to evaluate the effects of sorafenib in androgen-sensitive (LNCaP) and -insensitive (PC 3) prostate cancer cell lines...
  45. pmc Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer
    Ilaria Bellezza
    Department of Urology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, and Department of Pathology, General Hospital Feldkirch, Austria
    Am J Pathol 169:2199-208. 2006
    ..Collectively, our results show that SOCS-3 antagonizes regulation of cellular events by cAMP and is expressed in human prostate cancer...
  46. ncbi Identification of genes involved in estrogenic action in the human prostate using microarray analysis
    Jasmin Bektic
    Department of Urology, University of Innsbruck, Austria
    Genomics 83:34-44. 2004
    ..We identified a set of genes involved in a wide range of cellular functions that are potentially important for understanding the molecular basis of estradiol action in the prostate...
  47. ncbi Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion
    Hannes Neuwirt
    Department of Urology, Innsbruck Medical University, Anichtrasse 35, A 6020 Innsbruck, Austria
    Endocr Relat Cancer 14:1007-19. 2007
    ..Taken together with previous findings showing androgen receptor activation by IL-6, our results imply that androgen and cytokine signalling pathways interact at multiple levels in prostate cancer...
  48. ncbi Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328
    Hannes Steiner
    Department of Urology, Innsbruck Medical University, Innsbruck, Austria
    Prostate 66:1744-52. 2006
    ..Interleukin-6 (IL-6) is a multifunctional regulator of cellular events in prostate cancer. LNCaP-IL-6+ cells selected in the presence of IL-6 were taken for assessment of effects of the chimeric monoclonal anti-IL-6 antibody CNTO 328...
  49. doi Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways
    Martin Puhr
    Department of Urology, Innsbruck Medical University, Innsbruck, Austria
    Cancer Res 69:7375-84. 2009
    ..SOCS-3 knockdown results in an increase of cell death via activation of the extrinsic and intrinsic apoptosis pathways...
  50. pmc Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth
    Ilaria T Cavarretta
    Department of Urology, Innsbruck Medical University, Innsbruck, Austria
    Mol Ther 18:223-31. 2010
    ....
  51. ncbi Nuclear exclusion of the androgen receptor by melatonin
    Avi Rimler
    Department of Neurobiochemistry, The George S Wise Faculty of Life Sciences, Tel Aviv University, 69978 Tel Aviv, Israel
    J Steroid Biochem Mol Biol 81:77-84. 2002
    ..The nuclear localization of the AR is a hallmark of its cellular activity. These data point to AR nuclear exclusion as a possible mechanism to attenuate androgen responses in target tissues...
  52. doi 2-chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells
    Alba Minelli
    Dipartimento di Medicina Sperimentale Scienze Biochimiche, Sezione Biochimica Cellulare, Via del Giochetto, Perugia, Italy
    Prostate 68:360-72. 2008
    ..2-CADO inhibits the growth of PC3 cells by inducing apoptosis and cell cycle arrest through a mechanism that involves cellular uptake...
  53. doi Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells
    Shyh Han Tan
    Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Cancer Res 68:236-48. 2008
    ..The work presented here provides the first evidence of synergy between AR and the prolactin signaling protein Stat5a/b in human prostate cancer cells...
  54. ncbi Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival
    Barbara Wegiel
    Division of Pathology, Department of Laboratory Medicine, Lund University, University Hospital, Malmo, Sweden
    Int J Cancer 122:1521-9. 2008
    ..Taken together, IL6 might utilize PI3K/Akt and cyclin A1 to promote tumor cell survival in PCa...
  55. ncbi Androgen deprivation increases p300 expression in prostate cancer cells
    Hannelore V Heemers
    Departments of Urology Biochemistry and Molecular Biology and Laboratory Medicine Pathology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 67:3422-30. 2007
    ....
  56. ncbi A role for neurotensin in bicalutamide resistant prostate cancer cells
    Maria Vias
    Department of Oncology, Hutchison MRC Research Centre, CRUK Uro Oncology Group, University of Cambridge, Hills Road, Cambridge, United Kingdom
    Prostate 67:190-202. 2007
    ..However little attention has been paid to resistance pathways selected for by long-term treatment with non-steroidal anti-androgens...
  57. ncbi Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP)
    Shahriar Koochekpour
    Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Prostate 67:178-89. 2007
    ..Here, we explored the possibility for a functional relationship between prosaposin and androgen receptor (AR) in LNCaP cells...
  58. ncbi Mechanism of 2-chloroadenosine toxicity to PC3 cell line
    Alba Minelli
    Dipartimento di Medicina Sperimentale Scienze Biochimiche, Sezione Biochimica Cellulare, Via del Giochetto, Perugia, Italia
    Prostate 66:1425-36. 2006
    ..2-CADO inhibits the growth of several types of cells and causes apoptosis by a mechanism which involves adenosine receptors or cellular uptake or both...
  59. ncbi Interleukin-6 polymorphism: expression and pleiotropic regulation in human prostate cancer
    Zoran Culig
    J Urol 174:417. 2005